Overview
Dr. Gonzalez’s experiences have afforded a highly collaborative and multidisciplinary research program focused on advancing public health by promoting the safe, effective, and individualized use of drugs, with an emphasis on pediatric populations. His research interests include clinical pharmacology and applying mathematical modeling and simulation techniques to characterize the pharmacokinetics and pharmacodynamics of drugs, guide drug dosage selection, and improve drug safety. Dr. Gonzalez’s research program is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and he has published >115 peer-reviewed publications and >40 abstracts. He has been the major advisor for 8 PhD students (5 completed, 3 in training) and 15 postdoctoral fellows.
Current Appointments & Affiliations
Recent Publications
Oral Cephalexin Population Pharmacokinetics and Target Attainment Analysis in Infants 7-60 Days Old.
Journal Article J Pediatric Infect Dis Soc · October 2, 2025 BACKGROUND: There are limited data to guide oral antibiotic dosing in neonates and young infants, particularly for intravenous (IV) to oral transition. Cephalexin is a promising oral treatment for neonatal pathogens, including Enterobacterales and methicil ... Full text Link to item CitePhysiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity.
Journal Article J Clin Pharmacol · September 29, 2025 Oxcarbazepine (OXC) is a second-generation antiseizure medication, effective through its active metabolite, 10-mono-hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal-onset and primary generalized tonic-clonic seizures, with recommended ... Full text Link to item CiteExpansion of a Pharmacokinetic Model for Diazepam to Characterize Real-World IV and Oral Data in Children With and Without Obesity.
Journal Article J Clin Pharmacol · September 2025 Diazepam is a benzodiazepine approved for use in adults and children. The label incorporates recommended dosing for status epilepticus in children. Published population pharmacokinetic (PK) modeling recommends an intravenous bolus dose of 0.2 mg/kg capped ... Full text Link to item CiteRecent Grants
Best Pharmaceuticals for Children Act Pediatric Trials Network
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2032PTN 3.0 Task Order #2_ BPCA Pediatric Drug Development Clinical Trial Infrastructure
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030iPediHeart: Interdisciplinary Research Training Program for Pediatric Heart Disease
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2025 - 2030View All Grants